Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02938442 · ClinicalTrials.gov registry record · Phase 1
Vaccination of Triple Negative Breast Cancer Patients
A Phase 1 study, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT02938442 is a Phase 1 study that has completed, run by University of Arkansas. The registered enrollment target is 16 participants.
The verdict
NCT02938442, a Phase 1 study, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate a new investigational cancer vaccine, P10s-PADRE in combination with standard neoadjuvant chemotherapy and surgery in patients with clinical stage I, II or III triple negative breast cancer (TNBC). This study will compare the vaccine plus standard neoadjuvant chemotherapy and surgery to standard neoadjuvant chemotherapy and surgery alone.
Interventions
- DRUG Cyclophosphamide
- DRUG Doxorubicin
- DRUG Paclitaxel
- BIOLOGICAL P10s-PADRE with MONTANIDE™ ISA 51 VG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2019-01-25 |
| Est. Completion | 2023-01-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02938442
The ClinicalTrials.gov registry entry for NCT02938442 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT02938442 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02938442 about?
NCT02938442 is a clinical study titled "Vaccination of Triple Negative Breast Cancer Patients". The purpose of this study is to evaluate a new investigational cancer vaccine, P10s-PADRE in combination with standard neoadjuvant chemotherapy and surgery in patients with clinical stage I, II or III triple negative breast cancer (TNBC). This study will compare the vaccine plus standard neoadjuvant...
What is the current status of trial NCT02938442?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2019-01-25. Estimated completion is 2023-01-09.
What interventions are being tested in trial NCT02938442?
The interventions under investigation include: Cyclophosphamide (DRUG), Doxorubicin (DRUG), Paclitaxel (DRUG), P10s-PADRE with MONTANIDE™ ISA 51 VG (BIOLOGICAL).
Who is sponsoring clinical trial NCT02938442?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.